Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference

LAVAL, Quebec, Sept. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer; Linda LaGorga, senior vice president, Finance, and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications; are scheduled to participate at the Deutsche Bank 25(th) Annual Leveraged Finance Conference in Scottsdale, Ariz. on Oct. 4, 2017 at 8:00 a.m. MST (11:00 a.m. EDT).

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at: http://ir.valeant.com/events-and-presentations/2017.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

    Investor Contact:          Media Contact:

    Arthur Shannon             Lainie Keller

    arthur.shannon@valeant.com lainie.keller@valeant.com

    (514) 856-3855             (908) 927-0617

    (877) 281-6642 (toll free)

http://photos.prnewswire.com/prnvar/20101025/LA87217LOGO

View original content:http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-deutsche-bank-25th-annual-leveraged-finance-conference-300524740.html

SOURCE Valeant Pharmaceuticals International, Inc.